Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. Issue 5 (30th November 2022)

• Record Type: Journal Article
• Authors: Zhu, Yahui; Zhou, Jing; Zhu, Lijing; Hu, Wenjing; Liu, Baorui; Xie, Li
• Is Part Of: Human vaccines & immunotherapeutics. Volume 18:Issue 5(2022)
• Publication Date: 2022-11-30
• Subjects: Cervical cancer -- immune therapy -- adoptive tumor infiltrating lymphocytes -- potential strategies for improvement; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2022.2060019
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Cervical cancer is one of the most common malignancies among females. As a virus-related cancer, cervical cancer has attracted a lot of attention to develop virus-targeted immune therapy, including vaccine and adoptive immune cell therapy (ACT). Adoptive tumor infiltrating lymphocytes (TILs) cell therapy has been found to be able to control advanced disease progression in some cervical cancer patients who have received several lines of treatment in a pilot clinical trial. In addition, sustainable therapeutic effect has been identified in some cases. The safety risks of TIL therapy for patients are minimal or at least manageable. In this review, we focused on the versatility of TILs and tried to summarize potential strategies to improve the therapeutic effect of TILs and discuss related perspectives.